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Summary
Background: The aim of the study was to investigate the sensitivity of Procleix HIV1/HCV
Assay for HIV RNA and HCV RNA detection, and to analyse the frequency of viral nucleic
acid detection in blood donors with various EIA test results.
Material and methods: The 95% sensitivity of the Procleix test was 6.2 IU HCV RNA /ml
and 44.5 IU HIV RNA /ml. HCV RNA was detected in 71/392 (18.1%) anti-HCV positive and
HIV RNA in 21/557 (3.8%) EIA HIV-reactive donors. The frequency of HCV RNA detection
correlated with signal/cut-off ratios (S/C ratio) of EIA. HCV RNA was found in 68/105
(64.8%) of the donors if it was >4, in 1/85 (1.2%) if it was between 2.00 and 3.99, and in
2 out of 202 donors (1%) if it was between 1.00 and 1.99. HIV RNA was detected in all
21 blood donors positive in EIA and Western Blot.
Results and conclusions: The study demonstrated that Procleix HIV1/HCV Assay is very
sensitive and can be used in the reference laboratory to confirm active infection in donors with
positive results. We observed a low frequency of active infection in Polish blood donors with
repeated reactive results in HCV and HIV EIA. The high S/C ratio value (> 4) of EIA is
a good predictor of HCV RNA detection, but HCV RNA can also be detected in single donors
with low ratio values of the EIA test.
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Streszczenie
Wstęp: Celem pracy była ocena czułości wykrywania RNA HIV i RNA HCV metodą Procleix
HIV1/HCV oraz analiza częstości wykrywania materiału genetycznego wirusów u dawców
z różnymi wynikami testów przeglądowych anty-HCV i anty-HIV.
Materiał i metody: Dziewięćdziesięciopięcioprocentowa czułość testu Procleix wynosiła
6,2 IU RNA HCV /ml i 44,5 IU RNA HIV /ml. RNA HCV wykryto w 71/392 (18,1%)
dodatnich próbkach anty-HCV, zaś RNA HIV w 21/557 (3,8%) próbkach reaktywnych
w badaniu EIA HIV. Częstość wykrywania RNA HCV korelowała z wartością S/C uzyskaną
w badaniach immunoenzymatycznych. RNA HCV wykryto u 68/105 (64,8%) dawców z S/C > 4,
u 1/85 (1,2%) z S/C od 2,00 do 3,99 i u 2/202 dawców (1%) z S/C od 1,00 do 1,99. RNA HIV
wykryto u wszystkich 21 dawców z dodatnimi wynikami zarówno w badaniu EIA, jak
i w Western Blot.
Wyniki i wnioski: Procleix HIV1/HCV jest bardzo czułym testem i może być wykorzystywany
w laboratorium referencyjnym do potwierdzania aktywnego zakażenia u dawców z dodatnim
wynikiem immunoezymatycznych badań przeglądowych. Obserwowano małą częstość aktyw-
nych zakażeń u dawców z powtarzalnie dodatnimi wynikami badań anty-HCV i anty-HIV.
Wysoka wartość S/C (> 4) w EIA jest dobrym czynnikiem prognostycznym wykrycia RNA
HCV, aczkolwiek RNA HCV może być sporadycznie wykrywane u dawców z niższą wartością
S/C w EIA.
Słowa kluczowe: Anty-HCV, anty-HIV, RNA HIV, RNA HCV, amplifikacja przez transkrypcję
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Introduction
Screening blood donations for anti-HCV and
anti-HIV antibodies prevents transfusion-transmis-
sion of the hepatitis C virus (HCV) and human im-
munodeficiency virus (HIV). In Poland, in the first
year of anti-HCV screening (1994), 1.4% of blood
donors were found positive [1] and 0.14% were
found positive in 2003 (unpublished data). However,
not all anti-HCV positive donations were infectio-
us [2]. According to Polish regulations, all anti-HCV
and anti-HIV reactive blood donors are deferred
from the donor file and directed to a general practi-
tioner for further monitoring. Diagnostic confirma-
tory and supplementary procedure and subsequent
infectious marker monitoring are performed in the
Reference Laboratory at the Institute of Haemato-
logy and Transfusion Medicine in Warsaw [3]. All
anti-HIV positive sera are tested by Western Blot
to confirm the specificity of antibodies whereas anti-
HCV positives in all regular donors are tested by
Cobas Amplicor for HCV RNA to confirm the acti-
ve infection. In most HCV RNA negative samples,
a supplementary Western Blot test (RIBA) is also
performed.
The aim of the study was to validate the Proc-
leix HIV1/HCV Assay and to assess its usefulness
for HIV RNA and HCV RNA detection in blood do-
nors with positive results of EIA tests. We perfor-
med a comparative evaluation of HIV/HCV NAT
with screening HCV and HIV EIA assays used in
the Polish blood service.
Materials and methods
The analytical sensitivity of the Procleix HIV-1/
/HCV assay was determined by testing serial dilu-
tions of WHO International Standards: HCV RNA
(NIBSC 96/7901 — genotype 1) and HIV RNA
(NIBSC 97/656) (Table 1). Estimations of the 95%
and 50% detection limits of the assay were perfor-
med using Probit analysis.
In addition, the sensitivity of the Procleix as-
say against HCV genotypes 3a and 4c/d was analy-
sed by testing 4 dilutions in 8 repeats of 3 samples
anti-HCV neg/ HCV RNA pos for each genotype.
The HCV genotypes in those samples were inve-
stigated by InnoLipa HCV (Innogenetics, Belgium)
and the level of the virus by quantitative Amplicor
HCV MonitorTM version 2.0 (Roche Diag, Switzer-
land) (Table 2).
The specificity of the Procleix Assay was esti-
mated by simultaneously testing 291 anti-HCV/HIV
negative, RNA HCV/HIV negative samples with
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various concentrations of WHO HCV RNA and HIV
RNA standards and 6 highly viraemic HCV “win-
dow period” donations (3.93 × 106–4.78 × 107 IU
HCV RNA/ml).
Consecutive samples from blood donors with
repeat reactive (RR) or indeterminate results of EIA
anti-HCV (group I) or anti-HIV (group II) identified
during blood donor screening between May 2003
and June 2004 were sent to the Reference Labora-
tory and tested for HCV RNA and HIV RNA. Ac-
cording to Polish regulations, Vacutainer EDTA
tubes for molecular biology, with a gel barrier were
used (Becton Dickinson, UK or Sarstedt, Germa-
ny). Group I consisted of 392 blood donors with anti-
HCV RR EIA 3.0 (Ortho-Clinical Diag; S/C: >1) and
35 within “grey zone” results (S/C: 0.725–0.99).
Group II consisted of 557 blood donors with anti-
HIV screening EIA RR results (BioMerieux, S/C:
>1): 21 confirmed by Western Blot (WB) test, 244
with indeterminate WB results, and 292 negative
in WB. Moreover, 79 EIA indeterminate (S/C: 0.8–
–0.99)/WB negative and 62 indeterminate in both
EIA and WB plasma samples were tested.
Serological methods
Anti-HCV: EIA 3.0 (Ortho-Clinical Diag; USA),
UBI HCV EIA 4.0,
Anti-HIV: EIA HIV Uni-Form II Ag/Ab (bioMe-
rieux bv, Netherlands), Western Blot — New LAV
Blot I (BIO-RAD, France).
Molecular methods
Procleix HIV-1/HCV Assay (Gen-Probe/Chiron,
USA) for simultaneous detection of HIV-1 and HCV
RNA was performed in 500 ml of plasma according to
the manufacturer’s instruction. To discriminate the
presence of HCV RNA and/or HIV RNA, the initially
reactive samples were tested by discriminatory HCV
and HIV assays in 500 ml of plasma for each test. The-
se tests were performed in selected HCV and HIV
Table 1. HCV and HIV concentrations in WHO standard dilutions used to determine the analytical sensitivity of
the test
Tabela 1. Koncentracja HCV i HBV w rozcieńczeniach standardu WHO użytych do oceny czułości analitycznej
testu Procleix HIV1/HCV
HCV RNA IU/ml Number of samples tested HCV RNA IU/ml Number  of samples tested
HIV-1/HCV Discriminatory HIV-1/HCV Discriminatory
(duplex) (duplex)
HCV HIV HIV HCV
250 24 8 7 250 24 6 6
100 34 8 8 100 34 6 6
50 34 8 7 50 34 6 5
20 34 8 8 20 34 6 5
10 24 8 8 10 24 6 2
5 24 6 4 5 24 4 0
2,5 24 5 5
Table 2. HCV RNA concentration in dilutions of plasma samples with genotype 4c/4d and 3a
Tabela 2. Koncentracja HCV w rozcieńczeniach próbek osocza zakażonych genotypem 4c/4d i 3a
Genotype Donation number HCV RNA IU/ml concentration in dilutions tested
4c/4d 10-00-95111 5880, 588, 117, 29.25
17-00-100552 1800, 180, 36,18
12-02-127730 6730, 673, 134, 33.5
3a 06-00-69353 41600, 4160, 832, 41.6
009280 39300, 3930, 786, 39.3
010026 6460, 656, 129, 32.25
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positive standard (Table 1) and in all reactive blood
donor samples. In the discriminatory assay, HIV-1
specific probe and HCV specific probe were used
instead of the HIV-1 and HCV duplex probe reagent.
The assay procedure was the same as in the duplex
assay.
Results
Sensitivity of Procleix HIV-1/HCV
assay (duplex assay)
All samples (150/150) containing at least 10 IU
HCV RNA/ml (10, 20, 50, 100, and 250 IU HCV
RNA/ml) were positive in the Procleix Assay
(Figure 1). HCV RNA was detected in 39/48 sam-
ples containing 2.5–5 IU HCV RNA/ml. HIV RNA
was detected in all samples (58/58) containing at
least 100 IU HIV RNA/ml, in all but one (33/34)
standards with 50 IU HIV RNA/ml, in 24/34 stan-
dards with 20 IU HIV RNA/ml, and in 28/48 sam-
ples containing 5–10 IU HIV RNA/ml (Figure 2).
Probit analysis predicted 95% detection of HCV and
HIV at 6.2 IU/ml and 44.5 IU/ml, respectively, and
50% detection limit at 1.5 IU/ml and 6.8 IU/ml, re-
spectively (Table 3).
HCV genotype detection
HCV Genotypes 3 and 4 were detected in all
dilution repetitions including the lowest concen-
trations tested (18 IU/ml for 4c/d and 32 IU/ml
for 3a).
Specificity
None of the 291 anti-HCV/anti-HIV/HCV RNA
negative samples tested simultaneously with vario-
us concentrations of WHO HCV RNA and HIV RNA
standards and with 6 highly viremic HCV “window
period” donations (3.93 × 106–4.78 × 107 IU/ml)
was found positive. The frequency of invalid results
was 1/813 (0.12%).
HIV and HCV nucleic acid detection
in blood donors with different EIA results
HIV RNA was detected in all 21 anti-HIV EIA
positive/WB positive blood donors (Table 4). We did
not find any HIV RNA positive samples among do-
nors with EIA positive results not confirmed by We-
stern Blot (WB negative and indeterminate results,
n = 536) or in any EIA indeterminate (n = 141)
samples (Table 4). In 4 donors positive for anti-HIV
by EIA and WB and for HIV RNA by Procleix, HCV
RNA was also detected (all were anti-HCV positi-
ve as well).
HCV RNA was detected in 71/392 (18.1%) anti-
HCV EIA positive plasma samples (Table 5). Cor-
relation was observed between EIA S/C ratio and
HCV RNA detectability: HCV RNA was detected
in 68/105 (64.8%) of donors at ratio > 4, in 1/85
(1.2%) with S/C between 2.00 and 3.99, and in
2/202 donors (1%) with S/C between 1.00 and 1.99
Procleix HIV-1/HCV Assay results were negative
in all donors within “grey zone” (S/C ratio: 0.725–
–0.99) and in all those in the control group.
Figure 1. HCV RNA detection by Procleix HIV-1/HCV Assay in dilutions of HCV WHO standard
Rycina 1. Wykrywanie RNA HCV testem Procleix HIV-1/HCV w rozcieńczeniach standardu HCV WHO
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Figure 2. HIV RNA detection by Procleix HIV-1/HCV Assay in dilutions of HIV WHO standard
Rycina 2. Wykrywanie RNA HIV testem Procleix HIV-1/HCV w rozcieńczeniach standardu HIV WHO
Table 3. Estimation of 50% and 95% analytical sensitivity of the Procleix HIV-1/HCV Assay with 95% fiducial
intervals - Probit analysis results for HCV and HIV WHO Standards
Tabela 3. Analiza Probit wyników badania rozcieńczeń standardów HCV i HIV WHO – 50% i 95% czułość
analityczna testu
Sample/test 50% level 95% Fiducial interval 95% level 95% Fiducial interval
IU/ml  (IU/ml)  IU/ml  (IU/ml)
HIV – Duplex 6.8 (0.7, 12.8) 44.5 (21.9, 1472)
HCV – Duplex 1.5 (0.2, 2.4) 6.2 (4.3, 22.5)
HIV–Discriminatory 14.6 (6.7, 25.2) 55.1 (30.0, 495.5)
HCV–Discriminatory 2.2 6.7
Table 4. HIV RNA detection by Chiron TMA Assay in blood donor samples with different results in serological tests
Tabela 4. Wykrywanie RNA HIV testem Procleix HIV1/HCV w próbkach dawców krwi z różnymi wynikami
badań serologicznych
Results of serological tests HIV RNA detection by PROCLEIX HIV-1/HCV
EIA S/C Western Blot Number tested HIV RNA positives
Number Frequency
>1 + 21 21* 100%
>1 IND 244 0 0%
>1 – 292 0 0%
0.80–0.99 IND 62 0 0%
0.80–0.99 – 79 0 0%
*HIV/HCV S/C: 18.88–35.78; HIV S/C: 8.01–26.94, in 4 HCV RNA was also detected: HIV/HCV S/C: 29.23–35.78, HIV S/C: 22.03–26.62, HCV S/C: 18.55–23.83
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Discussion
The analytical sensitivity of the TMA based
assay is similar to the RT-PCR based assay. The
95% sensitivity of the Roche HCV Amplicor ran-
ges from 16 to 25 IU/ml depending on the isolation
applied [4]. For the Cobas Ampliscreen HIV-1 test,
it is 78.4 IU/ml [5]. For the TMA based assay used
in the present study, the 95% detection limit was
6.2 IU HCV RNA/ml and 44.5 IU HIV RNA/ml.
These results comply with the requirements of the
Committee for Proprietary Medical Products
(CPMP/BWP/390/97, 1998) of the Council of Europe
(100 IU/ml ~ 400 genomes equivalents per ml) [6].
HCV high variability and different genotype
distributions were reported by many authors world-
wide [7]. We confirm the high sensitivity of the
Chiron test for genotypes 1b, 3a, and 4, most fre-
quently detected in HCV infected Polish blood do-
nors [8].
The aim of the second part of the study was the
analysis of the usefulness of Procleix for the con-
firmation of active infection in blood donors with
positive results in serological tests. Our observa-
tions are similar to those of others who confirmed
HCV infection in no more than 30% of donors re-
peated reactive in screening viral enzyme immu-
noassays [9, 10]. Some other authors, however,
observed higher HCV confirmation rates in low risk
populations (75% — [11]).
We noticed that an S/C value of anti-HCV > 4 is
a good predictor of HCV RNA detection since the
frequency of positive results of HCV RNA was
64.8% in this group. This was confirmed by others,
who underline that the low-positive anti-hepatitis
C virus enzyme immunoassay result is a predictor
of low likelihood of hepatitis C infection [12]. In our
study, only 1.0% (3/287) of donors with S/C ratio
1–3.99 was infected.
It is difficult to interpret the anti-HCV positi-
ve/RNA negative results but we cannot entirely
exclude that such donors are infected. The fluctu-
ation of HCV RNA detectability in plasma and, the
presence of HCV RNA in mononuclear cells but not
in plasma have been described [13, 14]. For the
safety of blood transfusions, such individuals sho-
uld be treated as potentially infectious [14]. Such
a marker pattern is also characteristic for individu-
als who have recovered from HCV infection. The
frequency of spontaneous recovery is generally low;
it is estimated at 24–46% [15, 16]. The number of
prospective studies of such cases is still rather
small. In Poland, between January 2000 and Decem-
ber 2003, we identified 50 donors in the “window
period”. All of them seroconverted in the follow-
up study; 2 of 4 observed for >12 months, sponta-
neously cleared HCV RNA, but not anti-HCV [8].
The specificity of EIA for anti-HCV should
also be considered. The reasons for false positi-
vity of serological tests have been widely discus-
sed in literature. The changes in the EIA reacti-
vity are connected with lab-to-lab variation due
to different equipment, different technicians, and
different master lots used [17]. Vaccinations such
as influenza or rabies, acute infections and aller-
gies, immunologically related agents, such as
transplantation antigens, auto- and heterophile
antibodies, and reactivity to cellular and nondia-
gnostic proteins in the antigen preparation, were
reported to be associated with false-positive scre-
ening test results [17, 18].
The low frequency of active infections among
anti-HCV positive blood donors might also be con-
nected with the implementation of NAT for blood
Table 5. HCV RNA detection by Chiron TMA Assay in blood donor samples with different results in serological tests
Tabela 5. Wykrywanie RNA HCV testem Procleix HIV1/HCV w próbkach dawców krwi z różnymi wynikami
testów serologicznych
Anti-HCV EIA HCV RNA detection by PROCLEIX HIV-1/HCV
Result S/C range Number Tested HCV RNA positives
Number Frequency
“Grey zone” 0.725–0.99 35 0 0 %
 “Weak” positive 1–1.99 202 2* 1%
Positive 2–3.99 85 1** 1.2%
“Strong” Positive > 4.00 105 68*** 64.8%
*TMA HCV/HIV – S/C: 9.95–10.11, TMA HCV – S/C: 22.01; **TMA HCV/HIV – S/C: 11.18, TMA HCV – S/C: 22.20; ***TMA HCV/HIV – S/C: 9.00–12.53, TMA HCV –
S/C: 20.95–25.10
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donation screening in 2000. At present, by scre-
ening for HCV RNA, we select all HCV infected
blood donors before they become anti-EIA positive
and we remove them from the registry. Thus, we
reduce the number of HCV RNA positive donors
among the EIA RR regular blood donors.
The frequency of EIA false positive results
(536/557 — 96.2%) observed in anti-HIV EIA posi-
tive donors is even higher than anti-HCV EIA (321/
/392 — 81.9%). It is worth underlining that our stu-
dy showed full concordance between WB tests re-
sults and the confirmation of HIV infection by mole-
cular methods: HIV RNA was detected in all WB
positive samples and in none of the WB negative
ones. The reason for the high frequency of false po-
sitivity of anti-HIV EIA tests is not known. Ownby
observed that anti-HIV false positive result preva-
lence was higher among women [17]. The cross-re-
active antibodies resulting from alloimmunization
during pregnancy may contribute to the difference.
Some authors reported a trend toward declining pre-
valence with age [17]. In our study, false positive (not
confirmed in HIV RNA testing and in WB) anti-HIV
positive results were also two-fold more frequent
among women than men but the differences were not
statistically significant, probably due to the small
number of female donors. Preliminary evidence sug-
gests that low-risk subjects with indeterminate
Western Blot might be infected with HIV-related
viruses (other retroviruses) [19].
Our study shows that the HCV and HIV-1 TMA
duplex had high specificity and sensitivity and can
successfully be used to confirm infection in EIA
positive individuals. It is still to be considered, if
HCV RNA and HIV RNA testing might replace se-
rological tests, as in the case of WB for anti-HIV
and RIBA for anti-HCV. The second possibility,
which might considerably reduce the costs of con-
firming infection, is to make the confirmation algo-
rithm sequential with two EIA screening tests.
According to Allain and Seed, it is less laborious,
cheaper, and safe for blood donors [20, 10]. We also
propose to introduce external uniform quality con-
trol of viral screening tests for all blood centres to
limit the frequency of false positive results related
to human error or equipment.
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